Resultados a largo plazo del tratamiento con quimioterapia y radioterapia en linfoma no Hodgking localizado, de grados intermedio y alto

Background: Treatment of intermediate and high grade non-Hodgkin lymphoma (NHL) includes chemotherapy with or without radiotherapy, depending on the clinical stage. The standard treatment for advanced NHL is 8 cycles of combined chemotherapy, cyclophosphamide, adriamicin, vincristine and prednisone...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Ramírez V,Pablo, Ocqueteau T,Mauricio, Alvarez Z,Manuel, Bertín C-M,Pablo, Lira V,Pablo, Bustos C,Marisa, Besa de C,Pelayo
Lenguaje:	Spanish / Castilian
Publicado:	Sociedad Médica de Santiago 2006
Materias:	Chemotherapy Lymphoma, non-Hodgkin Radiotherapy
Acceso en línea:	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872006001100008
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:scielo:S0034-98872006001100008
record_format	dspace
spelling	oai:scielo:S0034-988720060011000082014-01-24Resultados a largo plazo del tratamiento con quimioterapia y radioterapia en linfoma no Hodgking localizado, de grados intermedio y altoRamírez V,PabloOcqueteau T,MauricioAlvarez Z,ManuelBertín C-M,PabloLira V,PabloBustos C,MarisaBesa de C,Pelayo Chemotherapy Lymphoma, non-Hodgkin Radiotherapy Background: Treatment of intermediate and high grade non-Hodgkin lymphoma (NHL) includes chemotherapy with or without radiotherapy, depending on the clinical stage. The standard treatment for advanced NHL is 8 cycles of combined chemotherapy, cyclophosphamide, adriamicin, vincristine and prednisone (CHOP). Patients presenting with localized disease are treated with fewer chemotherapy cycles and involved field radiotherapy, with good results. Aim: To evaluate the treatment results including overall survival (OS) and event-free survival (EFS) in localized aggressive NHL patients treated at the Pontificia Universidad Católica de Chile, Clinical Hospital. Patients and Methods: Retrospective analysis of all patients with Ann Arbor stages I and II referred to the hematology and radiotherapy clinic between 1998 and 2003. OS and EFS analysis was made according to the Kaplan and Meier method. Log-rank and Cox methods were used for univariate and multivariate analyses, respectively. Chemotherapy and radiotherapy toxicities were scored according to World Health Organization (WHO) and Radiation Therapy Oncology Group (RTOG) scales, respectively. Results: 39 patients (20 men), aged between 20 to 85 years, were the source for this study. The average follow-up was 51 months (range 6-115). The 5 years OS and EFS were 72,4% and 63,3%, respectively. On univariate analysis, age over 60 was the only variable that affected negatively OS and EFS. Acute toxicity caused by chemotherapy and radiotherapy was uncommon. Conclusions: Age over 60 was the only independent variable associated with poor prognosis. The number of chemotherapy cycles and the drug combination did not influence the results. These results support the usefullness of a shortened chemotherapy regimen plus involved field radiotherapyinfo:eu-repo/semantics/openAccessSociedad Médica de SantiagoRevista médica de Chile v.134 n.11 20062006-11-01text/htmlhttp://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872006001100008es10.4067/S0034-98872006001100008
institution	Scielo Chile
collection	Scielo Chile
language	Spanish / Castilian
topic	Chemotherapy Lymphoma, non-Hodgkin Radiotherapy
spellingShingle	Chemotherapy Lymphoma, non-Hodgkin Radiotherapy Ramírez V,Pablo Ocqueteau T,Mauricio Alvarez Z,Manuel Bertín C-M,Pablo Lira V,Pablo Bustos C,Marisa Besa de C,Pelayo Resultados a largo plazo del tratamiento con quimioterapia y radioterapia en linfoma no Hodgking localizado, de grados intermedio y alto
description	Background: Treatment of intermediate and high grade non-Hodgkin lymphoma (NHL) includes chemotherapy with or without radiotherapy, depending on the clinical stage. The standard treatment for advanced NHL is 8 cycles of combined chemotherapy, cyclophosphamide, adriamicin, vincristine and prednisone (CHOP). Patients presenting with localized disease are treated with fewer chemotherapy cycles and involved field radiotherapy, with good results. Aim: To evaluate the treatment results including overall survival (OS) and event-free survival (EFS) in localized aggressive NHL patients treated at the Pontificia Universidad Católica de Chile, Clinical Hospital. Patients and Methods: Retrospective analysis of all patients with Ann Arbor stages I and II referred to the hematology and radiotherapy clinic between 1998 and 2003. OS and EFS analysis was made according to the Kaplan and Meier method. Log-rank and Cox methods were used for univariate and multivariate analyses, respectively. Chemotherapy and radiotherapy toxicities were scored according to World Health Organization (WHO) and Radiation Therapy Oncology Group (RTOG) scales, respectively. Results: 39 patients (20 men), aged between 20 to 85 years, were the source for this study. The average follow-up was 51 months (range 6-115). The 5 years OS and EFS were 72,4% and 63,3%, respectively. On univariate analysis, age over 60 was the only variable that affected negatively OS and EFS. Acute toxicity caused by chemotherapy and radiotherapy was uncommon. Conclusions: Age over 60 was the only independent variable associated with poor prognosis. The number of chemotherapy cycles and the drug combination did not influence the results. These results support the usefullness of a shortened chemotherapy regimen plus involved field radiotherapy
author	Ramírez V,Pablo Ocqueteau T,Mauricio Alvarez Z,Manuel Bertín C-M,Pablo Lira V,Pablo Bustos C,Marisa Besa de C,Pelayo
author_facet	Ramírez V,Pablo Ocqueteau T,Mauricio Alvarez Z,Manuel Bertín C-M,Pablo Lira V,Pablo Bustos C,Marisa Besa de C,Pelayo
author_sort	Ramírez V,Pablo
title	Resultados a largo plazo del tratamiento con quimioterapia y radioterapia en linfoma no Hodgking localizado, de grados intermedio y alto
title_short	Resultados a largo plazo del tratamiento con quimioterapia y radioterapia en linfoma no Hodgking localizado, de grados intermedio y alto
title_full	Resultados a largo plazo del tratamiento con quimioterapia y radioterapia en linfoma no Hodgking localizado, de grados intermedio y alto
title_fullStr	Resultados a largo plazo del tratamiento con quimioterapia y radioterapia en linfoma no Hodgking localizado, de grados intermedio y alto
title_full_unstemmed	Resultados a largo plazo del tratamiento con quimioterapia y radioterapia en linfoma no Hodgking localizado, de grados intermedio y alto
title_sort	resultados a largo plazo del tratamiento con quimioterapia y radioterapia en linfoma no hodgking localizado, de grados intermedio y alto
publisher	Sociedad Médica de Santiago
publishDate	2006
url	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872006001100008
work_keys_str_mv	AT ramirezvpablo resultadosalargoplazodeltratamientoconquimioterapiayradioterapiaenlinfomanohodgkinglocalizadodegradosintermedioyalto AT ocqueteautmauricio resultadosalargoplazodeltratamientoconquimioterapiayradioterapiaenlinfomanohodgkinglocalizadodegradosintermedioyalto AT alvarezzmanuel resultadosalargoplazodeltratamientoconquimioterapiayradioterapiaenlinfomanohodgkinglocalizadodegradosintermedioyalto AT bertincmpablo resultadosalargoplazodeltratamientoconquimioterapiayradioterapiaenlinfomanohodgkinglocalizadodegradosintermedioyalto AT liravpablo resultadosalargoplazodeltratamientoconquimioterapiayradioterapiaenlinfomanohodgkinglocalizadodegradosintermedioyalto AT bustoscmarisa resultadosalargoplazodeltratamientoconquimioterapiayradioterapiaenlinfomanohodgkinglocalizadodegradosintermedioyalto AT besadecpelayo resultadosalargoplazodeltratamientoconquimioterapiayradioterapiaenlinfomanohodgkinglocalizadodegradosintermedioyalto
_version_	1718436292793991168

Resultados a largo plazo del tratamiento con quimioterapia y radioterapia en linfoma no Hodgking localizado, de grados intermedio y alto

Ejemplares similares